Chemical Structure (Clopidogrel 75mg Tab For Aurobindo 1)
Clopidogrel
Product Images NDC 33261-987
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 33261-987). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image Label (Clopidogrel 75mg Tab For Aurobindo 10)
This appears to be a description of a medication called Clopidogrel, which is a generic version of Plavix. The tablets contain 75mg of the active ingredient, and are made by AIDAREX PHARMACEUTICALS LLC and AUROBINDO PHARMA LTD. The tablets are pink and round, and should be taken every few hours as directed. There is also some information on how to store the medication properly.*
Figure 1: Exposure To Clopidogrel Active Metabolite Following Multiple Doses Of Clopidogrel Bisulfate 75 mg Alone Or With Proton Pump Inhibitors (ppis) (Clopidogrel 75mg Tab For Aurobindo 2)
The figure titled 'Exposure to Clopidogrel Active Metabolite Following Multiple Doses of Clopidogrel Bisulfate 75 mg Alone or with Proton Pump Inhibitors (PPIs)' presents the effect of coadministered PPIs on active metabolite AUC, with the mean and 90% confidence interval indicated. The four PPIs included in the graph are dexlansoprazole (60mg), lansoprazole (30mg), pantoprazole (80mg), and omeprazole (80mg). The X-axis shows the timepoints at which this effect was measured, and the Y-axis shows the change relative to clopidogrel bisulfate administered alone.*
Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel 75mg Tab For Aurobindo 3)
The image shows a graph titled "Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study." The horizontal axis represents months of follow-up, while the vertical axis represents the cumulative event rate in percentage. The graph contrasts the placebo group (treated with aspirin only) with a group treated with Clopidogrel Bisulfate and aspirin. Other standard therapies were used as appropriate but are not specified in the graph.*
Figure 3: Hazard Ratio For Patient Baseline Characteristics And On-study Concomitant Medications/interventions For The Cure Study (Clopidogrel 75mg Tab For Aurobindo 4)
Figure 4: Cumulative Event Rates For Death In The Commit Study* (Clopidogrel 75mg Tab For Aurobindo 5)
The text appears to show data related to event rates (death) in a study involving two groups - Placebo and a medication named "Ciopidogret". The data shows that the cumulative event rate for death was 6.1% in the Placebo group and 7.5% in the Ciopidogret group. It appears that the data also shows a proportional risk reduction in the Ciopidogret group before discharge. The study involved patients who all received aspirin. The data is plotted against days since randomization. It is not clear what the study was about or what the medication is used for.*
Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study* (Clopidogrel 75mg Tab For Aurobindo 6)
The text describes a figure showing the cumulative event rates for the combined endpoint of re-infarction, stroke or death in the COMMIT study. The figure includes data for patients who received avant (2910 patients, 10% of the total) and ciepidogror (2121 patients, 52% of the total). There was a proportional risk reduction (p=0.002) in the event rates over time (up to 28 days) since randomization. All patients in the study received aspirin.*
Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel 75mg Tab For Aurobindo 7)
The text appears to be a figure caption from a study, showing the effects of adding Clopidogrel Bisulfate to Aspirin on the combined primary endpoint across various baseline and medication subgroups. The figure includes odds ratios, confidence intervals, and percentage values. Therefore, it is not possible to generate any useful description without the actual figure.*
Figure 7: Effects Of Adding Clopidogrel Bisulfate To Aspirin In The Non-prespecified Subgroups In The Commit Study (Clopidogrel 75mg Tab For Aurobindo 8)
The text describes the effects of adding Clopidogrel Bisulfate to Aspirin in different subgroups of patients in the COMMIT study, including Killip class, previous MI, and infarct location. The results show odds ratios and confidence intervals for each subgroup, along with a global heterogeneity test. However, the specific values and interpretations of the results are not clear from the text.*
Figure 8: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel 75mg Tab For Aurobindo 9)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
